EUVIMEDEUVIMED entdecken
Crossref

Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time

Peng Wang iD, Richard Kenneth Yang iD, Fatima Zahra Jelloul iD, Rajyalakshmi Luthra iD, Mark J Routbort iD, Hui Chen iD, Sanam Loghavi, Chi Young Ok iD, Rashmi Kanagal-Shamanna iD, Sinchita Roy-Chowdhuri iD, L Jeffrey Medeiros iD, Keyur P Patel iD

JCO Precision Oncology · 2025

DOI: 10.1200/po.24.00299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Peng Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE A 70-gene liquid biopsy (LB) panel (LBP-70) was implemented at our institution to identify genetic alterations in the plasma of patients with solid tumors. We report the clinical utility of LBP-70 in a retrospective study of 1,243 consecutively tested patients. MATERIALS AND METHODS Electronic medical records were reviewed for relevant clinicopathologic and radiologic information and preanalytical variables, including circulating cell-free DNA yield. The clinical utility of the LBP-70 assay was evaluated on the basis of its ability to identify major tumor drivers and/or targetable alterations and the concordance of the LBP-70 results with tissue genotyping and radiologic findings. RESULTS Positive LB findings were reported in 75% of patients, ranging from 67% to 85% among various tumor types and 60% to 77% in different tumor stages within an average of seven workdays. The mutant allele frequency (AF) ranged from 0.1% to 90%, and 50% of the variants were detected at AF

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansLiquid BiopsyRetrospective StudiesMaleFemaleMiddle AgedAgedAdultAged, 80 and overMutation

Autor:innen und Institutionen

  • Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Peng Wang, Richard Kenneth Yang, Fatima Zahra Jelloul, Rajyalakshmi Luthra, Mark J Routbort, Hui Chen, Chi Young Ok, Rashmi Kanagal-Shamanna, Sinchita Roy-Chowdhuri, L Jeffrey Medeiros, Keyur P Patel

Zitieren

APA

Wang, P., Yang, R. K., Jelloul, F. Z., Luthra, R., Routbort, M. J., Chen, H., Loghavi, S., Ok, C. Y., Kanagal-Shamanna, R., Roy-Chowdhuri, S., Medeiros, L. J., & Patel, K. P. (2025). Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time. JCO Precision Oncology. https://doi.org/10.1200/po.24.00299

Vancouver

Wang P, Yang RK, Jelloul FZ, Luthra R, Routbort MJ, Chen H, et al. Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time. JCO Precision Oncology. 2025. doi:10.1200/po.24.00299

BibTeX
@article{Wang2025,
  author = {Wang, Peng and Yang, Richard Kenneth and Jelloul, Fatima Zahra and Luthra, Rajyalakshmi and Routbort, Mark J and Chen, Hui and Loghavi, Sanam and Ok, Chi Young and Kanagal-Shamanna, Rashmi and Roy-Chowdhuri, Sinchita and Medeiros, L Jeffrey and Patel, Keyur P},
  title = {Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po.24.00299}
}
Kostenlos starten →